Enhancing Innate Anti-Viral Resistance Through a Community-Based Intervention - Generation Xchange
Launched by UNIVERSITY OF CALIFORNIA, LOS ANGELES · Sep 6, 2022
Trial Information
Current as of August 21, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This randomized controlled intervention trial (planned n=160) will test whether participation in the Generation Xchange (GenX) intergenerational mentoring program can reduces vulnerability to respiratory virus infections (COVID, influenzas, colds), increase antiviral immune activity (Type I interferon responses), and reduce inflammatory immune activity in older African-American women and men living in a socioeconomically disadvantaged urban community. Blood samples will also be collected to determine which biological factors are most important in protecting older African-Americans from resp...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participating in the GenX intergenerational mentoring program
- • All GenX mentors \> 50 years of age are eligible to participate in this research
- * GenX program participation requires:
- • Reside in neighborhood of GenX schools (South-Central Los Angeles)
- • Pass basic literacy and cognitive function tests
- Exclusion Criteria:
- • Any health condition that would put participant at risk by enrollment/participation
About University Of California, Los Angeles
The University of California, Los Angeles (UCLA) is a prestigious academic institution renowned for its commitment to research and innovation in the biomedical field. As a clinical trial sponsor, UCLA leverages its cutting-edge facilities, expert faculty, and collaborative environment to advance medical knowledge and improve patient care. The university is dedicated to conducting rigorous clinical research that adheres to the highest ethical standards, aiming to translate scientific discoveries into effective therapies and interventions. Through its diverse array of clinical trials, UCLA seeks to address critical health challenges while fostering the development of future healthcare leaders.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Patients applied
Trial Officials
Steven Cole, Ph.D.
Principal Investigator
Professor of Medicine & Psychiatry
Teresa E Seeman, Ph.D.
Principal Investigator
Professor of Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials